The Children's Oncology Group Foundation

The Children's Oncology Group Foundation The Foundation allows philanthropic funds from individual supporters and organizations to go directly to COG to fund its much needed research.

The Children’s Oncology Group Foundation is a 501(c)(3) public charity that directs resources to support the Children's Oncology Group, which is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children’s Oncology Group Foundation enables COG's leadership, comprised of a team of doctors, nurses, laboratory scientists and other allied professionals, the ability to direct the resources raised for childhood cancer research to the areas of highest need and opportunity. In an era of rapid scientific discovery, this direct link allows COG researchers to respond quickly to new discoveries with the greatest potential to benefit children with cancer.

For Joe McDonough, founder of Andrew McDonough B+ Foundation, supporting childhood cancer research is deeply personal....
08/25/2026

For Joe McDonough, founder of Andrew McDonough B+ Foundation, supporting childhood cancer research is deeply personal.

When he learned that COG ACCL2531 needed philanthropic support to move forward, he raised his hand.

His support became one part of a much larger story of research, collaboration, and tenacity that brought the study to children. Now, COG ACCL2531 will test an intervention that could prevent serious infections during treatment for pediatric acute myeloid leukemia (AML).

Read the story behind the trial, and the people who said, “Yes,” to make it possible:
https://childrensoncologygroup.org/blog/2026/08/21/clinical-trial-cog-accl2351/

Before a new cancer treatment can become part of a larger clinical trial, researchers must first understand whether it i...
08/19/2026

Before a new cancer treatment can become part of a larger clinical trial, researchers must first understand whether it is safe and whether there is early evidence that it could be effective.

The Children’s Oncology Group’s Pediatric Early Phase-Clinical Trials Network (PEP-CTN) brings together 42 hospitals and research institutions across the United States, Canada and Australia to study promising new treatments for children and adolescents with leukemia, solid tumors and brain tumors.

By determining which therapies are ready to move forward, PEP-CTN helps turn promising ideas into future treatment possibilities for children with cancer.

Learn more about this important early-stage research:
https://childrensoncologygroup.org/about/pep-ctn/

Some childhood cancers affect fewer than 100 children each year. But no diagnosis is too rare, and no child should be le...
08/14/2026

Some childhood cancers affect fewer than 100 children each year. But no diagnosis is too rare, and no child should be left out of discovery.

Through Project:EveryChild, children and adolescents with cancer can contribute samples and information that help researchers better understand each diagnosis. Together, participants have helped build a resource containing more than 400,000 samples from nearly 300 different pediatric cancer diagnoses.

Each sample contributes valuable information that can lead to more precise treatments and better futures for children tomorrow.

Learn how Project:EveryChild is helping ensure that every child’s experience can contribute to progress: https://childrensoncologygroup.org/about/project-everychild/

Every new treatment begins with someone asking, "Can we do better?"Better survival rates.Better quality of life.Fewer lo...
07/31/2026

Every new treatment begins with someone asking, "Can we do better?"

Better survival rates.
Better quality of life.
Fewer long-term side effects.

Those questions set years of collaboration into motion before a clinical trial ever opens. It's work most people never see, but it's what creates new possibilities for children and families facing cancer.

Take a look behind the scenes to see how an idea becomes a clinical trial:

https://childrensoncologygroup.org/behind-the-scenes-how-research-ideas-become-cog-clinical-trials/

Thanks to decades of research, more children with T-cell blood cancers are surviving than ever before. But for patients ...
07/28/2026

Thanks to decades of research, more children with T-cell blood cancers are surviving than ever before. But for patients whose cancers relapse, outcomes are much less promising.

A new Children's Oncology Group clinical trial will explore ways to reduce the risk of relapse while also protecting children from lifelong side effects like learning challenges, hormone problems, and other complications that can result from treatment.

Read how this study builds on decades of collaborative research to turn findings into futures.

https://childrensoncologygroup.org/aall2331-t-cell-blood-cancer-trial/

No single hospital can solve childhood cancer alone. The biggest breakthroughs come from thousands of researchers, docto...
07/22/2026

No single hospital can solve childhood cancer alone. The biggest breakthroughs come from thousands of researchers, doctors, and institutions united by one goal: better outcomes for children with cancer.

Childhood and adolescent cancers are uncommon as compared with adult cancers, with only about 16,000 new cases per year in the United States. When diseases are this rare, no single hospital can effectively study them. Historically, this meant new therapies often took decades to develop because enrolling enough patients in a clinical trial was extremely challenging.

Scientific progress requires collaboration. Children’s Oncology Group (COG) unites a global network of over 13,500 experts and more than 220 institutions to advance pediatric cancer research.

At any given time, COG has more than 100 active clinical trials, with approximately 9,500 participants registered each year, giving patients access to new treatment approaches closer to home.

Data generated from COG research is shared across the research network. This collaborative model accelerates the pace of discovery and advances the development of new therapies for children and adolescents facing cancer.

See how researchers around the world are working together to turn discoveries into better treatments and brighter futures for children with cancer: https://childrensoncologygroup.org/about/impact/

Hope begins with research. At a time when research funding faces increasing challenges, your support is more important t...
07/16/2026

Hope begins with research. At a time when research funding faces increasing challenges, your support is more important than ever. Every gift brings us one step closer to better treatments, healthier survivors, and a future where no child dies of cancer.
Join us in making a difference.

https://childrensoncologygroup.org/ways-to-give/

One family's love for their daughter has grown into a movement that's inspiring the next generation.The young leaders o...
07/14/2026

One family's love for their daughter has grown into a movement that's inspiring the next generation.

The young leaders on the Caroline Symmes Children's Cancer Endowment Teen Board dedicate their time, energy, and hearts to raising funds for childhood cancer research and thoughtfully choose where those dollars will make the greatest impact.

We're honored that they selected Children's Oncology Group Foundation as one of their grant recipients. Read their inspiring story and see how they're helping create a brighter future for children with cancer.
https://childrensoncologygroup.org/caroline-symmes-childrens-cancer-endowment/

For adolescents diagnosed with advanced Hodgkin lymphoma, cancer treatment can mean months away from school, long hospit...
07/07/2026

For adolescents diagnosed with advanced Hodgkin lymphoma, cancer treatment can mean months away from school, long hospital stays, countless miles traveled for care, and years of monitoring for long-term side effects.

That's why the March 2026 FDA approval of nivolumab in combination with chemotherapy for newly diagnosed Stage III and Stage IV classic Hodgkin lymphoma is so meaningful.

For survivor and COG Patient Advocate Emilie Lynch, this milestone is deeply personal. Diagnosed at age 16, Emilie spent months in treatment, endured long commutes for radiation, and continues to navigate the lasting effects of therapy years later.

Having experienced firsthand how cancer treatment affects patients and families long after therapy ends, she hopes this new treatment approach will allow future patients to spend less time in the hospital and more time simply being kids.

This approval offers hope not only for better outcomes, but for a better quality of life for patients, survivors, and the families who walk every step of the cancer journey alongside them.

Read more about the potential impact of this achievement: https://childrensoncologygroup.org/immunotherapy-changes-the-future-of-hodgkin-lymphoma-treatment/

Address

Philadelphia, PA

Telephone

+12672777064

Website

Alerts

Be the first to know and let us send you an email when The Children's Oncology Group Foundation posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category